1. Home
  2. HWKN vs MLYS Comparison

HWKN vs MLYS Comparison

Compare HWKN & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hawkins Inc.

HWKN

Hawkins Inc.

HOLD

Current Price

$134.95

Market Cap

2.7B

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$39.40

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HWKN
MLYS
Founded
1938
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.9B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
HWKN
MLYS
Price
$134.95
$39.40
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$200.00
$46.40
AVG Volume (30 Days)
147.6K
1.8M
Earning Date
10-29-2025
11-10-2025
Dividend Yield
0.56%
N/A
EPS Growth
1.59
N/A
EPS
3.97
N/A
Revenue
$1,045,229,000.00
N/A
Revenue This Year
$15.55
N/A
Revenue Next Year
$6.48
N/A
P/E Ratio
$34.13
N/A
Revenue Growth
11.86
N/A
52 Week Low
$98.30
$8.24
52 Week High
$186.15
$47.65

Technical Indicators

Market Signals
Indicator
HWKN
MLYS
Relative Strength Index (RSI) 47.44 44.02
Support Level $127.65 $41.50
Resistance Level $132.48 $44.13
Average True Range (ATR) 5.50 3.07
MACD 2.35 -0.49
Stochastic Oscillator 93.13 40.44

Price Performance

Historical Comparison
HWKN
MLYS

About HWKN Hawkins Inc.

Hawkins Inc manufactures and sells a variety of chemicals and ingredients. The firm organizes itself into three segments based on the product type. The industrial segment, which generates the majority of revenue, sells private label bleach, caustic soda, sulfuric acid, hydrochloric acid, phosphoric acid, potassium hydroxide, and aqua ammonia. The water treatment segment sells chemicals and equipment used to treat potable water, municipal and industrial wastewater, industrial process water, and non-residential swimming pool water. The health and nutrition segment sells ingredients to food, beverage, personal care, and dietary supplement producers. The majority of revenue is gained from Water Treatment.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: